Full Prescribing Information |This site is intended for US healthcare professionals.

Ordering & support

An easy ordering process with several options

Image of Dysport injection 500 unit vial

500-U Vial
NDC 15054-0500-01*

Image of Dysport injection 300 unit vial

300-U Vial
NDC 15054-0530-06*

Each box contains 1 sterile, single-use vial with accompanying Full Prescribing Information and Medication Guide.

To help you order Dysport quickly and easily: Choose practice type

*Please note that for billing purposes the NDC number requires 11 digits. Therefore, a zero must be entered into the 10th position (eg, "15054-0500-01"). This is consistent with Redbook and First Databank listings.

Dysport Resource Guide

Contains important reimbursement, billing, and coding information


Want more information?

Contact a Dysport sales representative or reimbursement specialist who can help


How to identify authentic Dysport for therapeutic uses

The best way to ensure your patients are receiving authentic Dysport® is to order from an authorized Dysport distributor. See below for the various things you can check on each Dysport package to make sure it is authentic. There are more anti-counterfeiting measures on the packaging that aren't listed here. Ask your distributor for more information.

Dysport® (abobotulinumtoxinA) vial product image 300 units
Dysport® (abobotulinumtoxinA) vial product image 500 units

300 units/vial

Dysport® (abobotulinumtoxinA) vial product image 300 units

500 units/vial

Dysport® (abobotulinumtoxinA) vial product image 500 units

Patient support


(Coverage, Access, Reimbursement, & Education Support)

Ipsen Cares for Dysport

The IPSEN CARES® program was designed to help you:

Navigate the insurance coverage process

Provide copay assistance for eligible* patients

Provide free medication to eligible* patients through the Patient Assistance Program

Avoid delays or interruptions in therapy

*See eligibility criteria at www.IPSENCARES.com.

or call (866) 435-5677 to speak to an IPSEN CARES® Patient Access Specialist

Patient savings on private insurance copay, deductible, and coinsurance costs

Savings may be applied for up to 4 injections per calendar year

Eligible* patients may receive up to $5,000:

Beginning or currently receiving treatment with Dysport

Currently have commercial insurance that covers the medication and associated costs of Dysport, or uninsured patients who pay their entire out-of-pocket cost

In any calendar year commencing January 1, the maximum copay benefits paid by Ipsen Biopharmaceuticals, Inc., will be $5,000 covering no more than (4) Dysport treatments. For cash-pay patients, the maximum copay benefit amount for eligible Dysport treatment is $1,250, subject to the annual maximum of $5,000 in total. There could be additional financial responsibility depending on the patient's insurance plan.

National dysport coverage overview

For adults with spasticity

For adult patients with upper limb spasticity or lower limb spasticity, Dysport has national coverage without restrictions* for:

97% Commercial

100% Medicare (Part B)

95% Medicare (Part D)

93% Medicaid

This document represents no promise or guarantee concerning coverage or levels of reimbursement. It is recommended that you contact your local payers with regard to local reimbursement policies and practices. Please consult your counsel or reimbursement specialist on reimbursement or billing questions specific to your practice.

Coverage data provided by Zitter Health Insights and current as of June 2018.

*Limitations/conditions placed by payers that are aligned with or broader than Dysport’s FDA-approved indications.

Medicaid covers both state and managed Medicaid plans.

Additional Resources

Dosing & Dilution Guide (Adult with Spasticity or Cervical Dystonia)

Adult Spasticity Injection Tracker

This illustration explains eight different muscles for administering Dysport (abobotulinumtoxinA) injection for patients with upper limb spasticity

Copay Brochure

Copay Brochure

Copay Assistance Program Flash Card

Copay Brochure

A Treatment Guide for Adult Spasticity

Dysport Patient Brochure

Dilution Poster

Dysport Patient Brochure

Adult Spasticity Patient Profile

This illustration explains eight different muscles for administering Dysport (abobotulinumtoxinA) injection for patients with upper limb spasticity

Organizations that provide patients with valuable information and support












Important Safety Information

Warning: Distant Spread of Toxin Effect

Postmarketing reports indicate that the effects of Dysport® (abobotulinumtoxinA) and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including upper limb spasticity in children, and in approved indications, cases of spread of effect have been reported at doses comparable to or lower than the maximum recommended total dose.


Dysport is contraindicated in patients with known hypersensitivity to any botulinum toxin products, cow’s milk protein, components in the formulation or infection at the injection site(s). Serious hypersensitivity reactions including anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea have been reported. If such a reaction occurs, discontinue Dysport and institute appropriate medical therapy immediately.

Warnings and Precautions

Lack of Interchangeability Between Botulinum Toxin Products

The potency Units of Dysport are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products, and, therefore, units of biological activity of Dysport cannot be compared to or converted into units of any other botulinum toxin products assessed with any other specific assay method.

Dysphagia and Breathing Difficulties

Treatment with Dysport and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or swallowing. When distant side effects occur, additional respiratory muscles may be involved. Deaths as a complication of severe dysphagia have been reported after treatment with botulinum toxin. Dysphagia may persist for several weeks, and require use of a feeding tube to maintain adequate nutrition and hydration. Aspiration may result from severe dysphagia and is a particular risk when treating patients in whom swallowing or respiratory function is already compromised. Patients treated with botulinum toxin may require immediate medical attention should they develop problems with swallowing, speech, or respiratory disorders. These reactions can occur within hours to weeks after injection with botulinum toxin.

Pre-existing Neuromuscular Disorders

Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junction disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) should be monitored particularly closely when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of Dysport.

Human Albumin and Transmission of Viral Diseases

This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), but if that risk actually exists, the risk of transmission would also be considered extremely remote. No cases of transmission of viral diseases, CJD, or vCJD have ever been identified for licensed albumin or albumin contained in other licensed products.

Intradermal Immune Reaction

The possibility of an immune reaction when injected intradermally is unknown. The safety of Dysport for the treatment of hyperhidrosis has not been established. Dysport is approved only for intramuscular injection.

Most Common Adverse Reactions

Adults with upper limb spasticity (≥2% and greater than placebo): nasopharyngitis, urinary tract infection, muscular weakness, musculoskeletal pain, dizziness, fall, and depression.

Adults with lower limb spasticity (≥5% and greater than placebo): falls, muscular weakness, and pain in extremity.

Adults with cervical dystonia (≥5% and greater than placebo): muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, musculoskeletal pain, dysphonia, injection site pain, and eye disorders.

Pediatric patients with lower limb spasticity (≥10% and greater than placebo): upper respiratory tract infection, nasopharyngitis, influenza, pharyngitis, cough, and pyrexia.

Drug Interactions

Co-administration of Dysport and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like agents), or muscle relaxants, should be observed closely because the effect of botulinum toxin may be potentiated. Use of anticholinergic drugs after administration of Dysport may potentiate systemic anticholinergic effects, such as blurred vision. The effect of administering different botulinum neurotoxins at the same time or within several months of each other is unknown. Excessive weakness may be exacerbated by another administration of botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin. Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of Dysport.

Special Populations
Use in Pregnancy

Based on animal data, Dysport may cause fetal harm. There are no adequate and well-controlled studies in pregnant women. Dysport should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Pediatric Use

Based on animal data Dysport may cause atrophy of injected and adjacent muscles; decreased bone growth, length, and mineral content; delayed sexual maturation; and decreased fertility.

Geriatric Use

In general, elderly patients should be observed to evaluate their tolerability of Dysport, due to the greater frequency of concomitant disease and other drug therapy. Subjects aged 65 years and over who were treated with Dysport for lower limb spasticity reported a greater percentage of fall and asthenia as compared to those younger (10% vs. 6% and 4% vs. 2%, respectively).

To report SUSPECTED ADVERSE REACTIONS or product complaints, contact Ipsen at 1-855-463-5127. You may also report SUSPECTED ADVERSE REACTIONS to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Dysport for injection is indicated for the treatment of:

  • Adults with cervical dystonia
  • Spasticity in adult patients
  • Lower limb spasticity in pediatric patients 2 years of age and older

Please see full Prescribing Information, including Boxed Warning and Medication Guide.


Dysport® (abobotulinumtoxinA) for injection is indicated for the treatment of:

The safety and effectiveness of Dysport® injected into upper limb muscles or proximal muscles of the lower limb for the treatment of spasticity in pediatric patients has not been established.

Safety and effectiveness in pediatric patients with lower limb spasticity below 2 years of age have not been evaluated.

Safety and effectiveness in pediatric patients with cervical dystonia or upper limb spasticity have not been established.

Click here for Full Prescribing Information and Medication Guide

Leaving Website

NOTE: You are about to leave the Ipsen Biopharmaceuticals, Inc. Dysport® (abobotulinumtoxinA) website. This link is provided to you as a service to our website visitors. It will take you to another site maintained by a third party who is solely responsible for its content.

Ipsen Biopharmaceuticals, Inc. does not control or endorse this site. Ipsen is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit. Click “OK” to proceed or “CANCEL” to return to dysporthcp.com.

Are You a Healthcare Professional?

This site is intended for US healthcare professionals only. By clicking YES, you attest that you are a healthcare professional licensed in the US.

Dysport® (abobotulinumtoxinA) Logo Transparent

You’re going to the Dysport® (abobotulinumtoxinA) for aesthetic use website.

NOTE: You are about to leave the Dysport® (abobotulinumtoxinA) website. When you click below, you will be leaving Dysport.com, a Ipsen Biopharmaceuticals, Inc. property, and will be directed to DysportUSA.com, which is owned by Galderma. Galderma Laboratories, L.P., is solely responsible for its content.

Ipsen Biopharmaceuticals, Inc. does not control this site. Ipsen is not responsible for the privacy policy on Galderma websites. We encourage you to read the privacy policy of every website you visit. Click “OK” to proceed or “CANCEL” to return to dysporthcp.com.

Leaving Website

NOTE: You are about to leave the Ipsen Biopharmaceuticals, Inc. Dysport® (abobotulinumtoxinA) website. This link is provided as a service to our website visitors. It will take you to another site maintained by Ipsen. Click "OK" to proceed or "CANCEL" to return to dysporthcp.com.

If you practice within an institution:

Please acquire Dysport® (abobotulinumtoxinA) from your wholesalers

If in a private practice or clinic, please select the applicable coverage benefit to acquire Dysport® (abobotulinumtoxinA):

If Dysport® (abobotulinumtoxinA) is covered under the medical benefit, choose the best option for your office:

To purchase Dysport® (abobotulinumtoxinA) directly (buy and bill):

  • Requires upfront financial investment
  • Your office acquires Dysport® directly from a select group of Specialty Distributors
  • Your office collects copay/coinsurance directly from the patient
  • Your office seeks reimbursement from payer(s)

To purchase from authorized specialty distributors of record, select from the distributors below:

Besse Medical

Call 1-800-543-2111

Order online

Cardinal Specialty

Call 1-866-300-3838

Order online

CuraScript SD

Call 1-877-599-7748

Order online

McKesson Specialty Health

Call 1-855-477-9800

Order online

If Dysport® (abobotulinumtoxinA) is covered under the pharmacy benefit, IPSEN CARES® can help you find a network specialty pharmacy:

Call IPSEN CARES® at 1-866-435-5677,

Monday-Friday, from 8:00 AM to 8:00 PM ET (5:00 AM to 5:00 PM PT).

To purchase from specialty pharmacy assignment of benefit (AOB):

  • No upfront financial investment
  • IPSEN CARES® can provide helpful information on selecting the appropriate Specialty Pharmacy Provider by calling 1-866-435-5677
  • Patient pays copay/coinsurance directly to Specialty Pharmacy
  • Specialty Pharmacy ships product directly to your office

Call IPSEN CARES® at 1-866-435-5677,

Monday-Friday, from 8:00 AM to 8:00 PM ET (5:00 AM to 5:00 PM PT).